Conditional Survival After Surgical Intervention in Patients With Non-Small Cell Lung Cancer Takayuki Fukui, MD, Toshiki Okasaka, MD, Koji Kawaguchi,

Slides:

Advertisements

Similar presentations

Jeffrey M. Griffin, MD, MS, Carolyn E. Reed, MD, Chadrick E

Advertisements

Elizabeth A. David, MD, David T

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Amanda L

Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes Meng S. Shao, MD, Andrew T. Wong, MD,

Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease Anders Bugge, MD, May Brit Lund, MD, PhD, Cathrine.

Complete Thoracic Mediastinal Lymphadenectomy Leads to a Higher Rate of Pathologically Proven N2 Disease in Patients With Non-Small Cell Lung Cancer

Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F

Surgical Management of Advanced Non-Small Cell Lung Cancer Is Decreasing But Is Associated With Improved Survival Elizabeth A. David, MD, Robert J. Canter,

Comparison of Thoracoscopic Segmentectomy and Thoracoscopic Lobectomy for Small-Sized Stage IA Lung Cancer Chenxi Zhong, MD, Wentao Fang, MD, Teng Mao,

Rodrigo A. S. Sardenberg, MD, Clovis Pinto, MD, Cynthia A

Chun Chieh Lin, PhD, MBA, Matthew P

Joshua E. Rosen, BASc, Hari B

Sarcomatoid Carcinoma of the Lung: A Predictor of Poor Prognosis

Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer Seong Yong Park, MD, Hyun-Sung Lee, MD, PhD, Hee-Jin Jang, MD, Geon Kook.

Oncologic Outcomes After Surgical Resection of Subcentimeter Non-Small Cell Lung Cancer Matthew J. Schuchert, MD, Arman Kilic, BS, Arjun Pennathur, MD,

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD

Clinical Prognosis of Superior Versus Basal Segment Stage I Non-Small Cell Lung Cancer Yoshinori Handa, MD, Yasuhiro Tsutani, MD, PhD, Norifumi Tsubokawa,

Prognostic Factors Associated With Interventional Bronchoscopy in Lung Cancer Nicolas Guibert, MD, Julien Mazieres, MD, PhD, Benoît Lepage, MD, Gavin.

Morbidity, Survival, and Site of Recurrence After Mediastinal Lymph-Node Dissection Versus Systematic Sampling After Complete Resection for Non-Small.

Benjamin E. Lee, MD, Mark Shapiro, MD, John R. Rutledge, MAS, Robert J

Video-Assisted Thoracic Surgery Lobectomy: Experience With 1,100 Cases

Metachronous Germ Cell Tumors of the Mediastinum

High Expression of Zinc-Binding Protein-89 Predicts Decreased Survival in Esophageal Squamous Cell Cancer Shu-Mei Yan, MD, Hui-Ni Wu, MB, Fan He, MD,

Lobectomy in Octogenarians With Non-Small Cell Lung Cancer: Ramifications of Increasing Life Expectancy and the Benefits of Minimally Invasive Surgery

Induction Chemotherapy is Not Superior to a Surgery-First Strategy for Clinical N1 Non- Small Cell Lung Cancer Paul J. Speicher, MD, Zachary W. Fitch,

David T. Cooke, MD, Danh V. Nguyen, PhD, Ying Yang, MS, Steven L

Lymph Node Evaluation Achieved by Open Lobectomy Compared With Thoracoscopic Lobectomy for N0 Lung Cancer Robert E. Merritt, MD, Chuong D. Hoang, MD,

Prognostic Predictors in Non-Small Cell Lung Cancer Patients Undergoing Intentional Segmentectomy Terumoto Koike, MD, PhD, Teruaki Koike, MD, PhD, Yasushi.

Surgical Treatment of Metachronous Second Primary Lung Cancer

Andrea S. Wolf, MD, MPH, Scott J

Community-Based Multidisciplinary Computed Tomography Screening Program Improves Lung Cancer Survival Daniel L. Miller, MD, William R. Mayfield, MD,

Long-Term Outcomes After Surgical Resection of Pulmonary Metastases From Colorectal Cancer Hisashi Suzuki, MD, PhD, Moriyuki Kiyoshima, MD, Miyuki Kitahara,

Resection of Intraabdominal Tumors With Cavoatrial Extension Using Deep Hypothermic Circulatory Arrest Christopher Lau, MD, Padraic O’Malley, MD, Mario.

Lung Cancer Surgery in Patients With Liver Cirrhosis

Conditional Cancer-Specific Versus Cardiovascular-Specific Survival After Lobectomy for Stage I Non-Small Cell Lung Cancer Shawn S. Groth, MD, MS, Natasha.

Asad A. Shah, MD, Mathias Worni, MD, MHS, Christopher R

Improved Lymph Node Staging in Early-Stage Lung Cancer in the National Cancer Database Seth B. Krantz, MD, Waseem Lutfi, BS, Kristine Kuchta, MS, Chi-Hsiung.

Prognostic factors in clinical stage I non–small cell lung cancer

Influence of Cigarette Smoking on Survival and Tumor Invasiveness in Clinical Stage IA Lung Adenocarcinoma Ryo Maeda, MD, Junji Yoshida, MD, Genichiro.

Use of Amiodarone After Major Lung Resection

Elliot Wakeam, MD, MPH, James P. Byrne, MD, Gail E

Abel Gómez-Caro, MD, Pedro Arguis, MD The Annals of Thoracic Surgery

Smoking Status as a Prognostic Factor in Patients with Stage I Pulmonary Adenocarcinoma Ichiro Yoshino, MD, PhD, Daigo Kawano, MD, Taro Oba, MD, Koji.

Recurrence and Survival After Segmentectomy in Patients With Prior Lung Resection for Early-Stage Non-Small Cell Lung Cancer Lisa M. Brown, MD, Brian.

Subcategorization of Lung Cancer Based on Tumor Size and Degree of Visceral Pleural Invasion⁎ Noriaki Sakakura, MD, Shoichi Mori, MD, Katsuhiro Okuda,

Brendon M. Stiles, MD, Mohamed K. Kamel, MD, Sebron W

Differences in Patterns of Recurrence in Early-Stage Versus Locally Advanced Non- Small Cell Lung Cancer Feiran Lou, MD, MS, Camelia S. Sima, MD, MS,

Predictors of Long-Term Survival After Resection of Esophageal Carcinoma With Nonregional Nodal Metastases Paul C. Lee, MD, Jeffrey L. Port, MD, Subroto.

Surgical Therapy for Bilateral Multiple Primary Lung Cancer

High Expression of p300 Has an Unfavorable Impact on Survival in Resectable Esophageal Squamous Cell Carcinoma Yong Li, MD, Hao-Xian Yang, MD, Rong-Zhen.

Trimodality Therapy for Lung Cancer With Chest Wall Invasion: Initial Results of a Phase II Study Koji Kawaguchi, MD, Kohei Yokoi, MD, Hiroshi Niwa,

Selective Mediastinal Lymphadenectomy for Clinico-Surgical Stage I Non–Small Cell Lung Cancer Morihito Okada, MD, PhD, Toshihiko Sakamoto, MD, PhD, Tsuyoshi.

Radiofrequency Ablation for Stage I Non-Small Cell Lung Cancer: Management of Locoregional Recurrence Michael Lanuti, MD, Amita Sharma, MD, Henning Willers,

Clinicopathologic Features and Computed Tomographic Findings of 52 Surgically Resected Adenosquamous Carcinomas of the Lung Yukio Watanabe, MD, Koji.

Phillip G. Rowse, MD, Dawn E

Surgical Treatment for Limited-Stage Primary Small Cell Cancer of the Esophagus Dongrong Situ, MD, Yongbin Lin, MD, PhD, Hao Long, MD, PhD, Lanjun Zhang,

Arman Kilic, BS, Matthew J. Schuchert, MD, Brian L

Subcategorization of Resectable Non-Small Cell Lung Cancer Involving Neighboring Structures Noriaki Sakakura, MD, Shoichi Mori, MD, Futoshi Ishiguro,

Prognosis of Patients With Pathologic T0 N+ Esophageal Squamous Cell Carcinoma After Chemoradiotherapy and Surgical Resection: Results From a Nationwide.

Shared Decision Making and Effective Risk Communication in the High-Risk Patient With Operable Stage I Non-Small Cell Lung Cancer Pamela Samson, MD,

Resected Synchronous Primary Malignant Lung Tumors: A Population-Based Study Hans Rostad, MD, PhD, Trond-Eirik Strand, MD, Anne Naalsund, MD, Jarle Norstein,

Neal S Goldstein, MD The Annals of Thoracic Surgery

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Survival Benefits of Postoperative Chemoradiation for Lymph Node–Positive Esophageal Squamous Cell Carcinoma Po-Kuei Hsu, MD, Chien-Sheng Huang, MD,

Clinical Outcome After Pulmonary Resection for Lung Cancer Patients on Hemodialysis Toshiro Obuchi, MD, Wakako Hamanaka, MD, Yasuhiro Yoshida, MD, Jun.

Survival and Outcomes of Pulmonary Resection for Non-Small Cell Lung Cancer in the Elderly: A Nested Case-Control Study Robert J. Cerfolio, MD, Ayesha.

Mark I. Block, MD The Annals of Thoracic Surgery

Domenico Galetta, MD, PhD, Lorenzo Spaggiari, MD, PhD

Early Surgical Results After Pneumonectomy for Non-Small Cell Lung Cancer are not Affected by Preoperative Radiotherapy and Chemotherapy Tomas Gudbjartsson,

Presentation transcript:

Conditional Survival After Surgical Intervention in Patients With Non-Small Cell Lung Cancer Takayuki Fukui, MD, Toshiki Okasaka, MD, Koji Kawaguchi, MD, Koichi Fukumoto, MD, Shota Nakamura, MD, Shuhei Hakiri, MD, Naoki Ozeki, MD, Kohei Yokoi, MD The Annals of Thoracic Surgery Volume 101, Issue 5, Pages 1877-1882 (May 2016) DOI: 10.1016/j.athoracsur.2015.11.067 Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

Fig 1 Overall survival curves of the cohort stratified by pathologic stage. The cumulative 5-year survival rate of each stage is shown. The Annals of Thoracic Surgery 2016 101, 1877-1882DOI: (10.1016/j.athoracsur.2015.11.067) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

Fig 2 The changes of 5Y-CS based on (A) overall survival, (B) lung cancer–specific survival, and (C) recurrence-free survival. In this study, 5Y-CS(x) was defined as the survival probability of the next 5 years at some years after operation (x). The 5Y-CS(1), 5Y-CS (2), 5Y-CS(3), and 5Y-CS(4) in all patients showed gradual improvement. The Annals of Thoracic Surgery 2016 101, 1877-1882DOI: (10.1016/j.athoracsur.2015.11.067) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

Fig 3 The change in 5Y lung cancer–specific CS when adjusted for (A) age, (B) sex, (C) histologic type, or (D) smoking status. The Annals of Thoracic Surgery 2016 101, 1877-1882DOI: (10.1016/j.athoracsur.2015.11.067) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

Fig 4 The changes of 5Y-CS(0), 4Y-CS(1), 3Y-CS(2), 2Y-CS(3), and 1Y-CS(4) based on (A) overall survival, (B) lung cancer–specific survival, and (C) recurrence-free survival. These factors were defined as the probability of surviving at 5 postsurgical years after a specific time. The Annals of Thoracic Surgery 2016 101, 1877-1882DOI: (10.1016/j.athoracsur.2015.11.067) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

Fig 5 (A and B) The change in 5Y-CS and 5Y-CS(0), 4Y-CS(1), 3Y-CS(2), 2Y-CS(3), and 1Y-CS(4) in women and those with adenocarcinoma histologic type, pathologic stage I, and normal serum carcinoembryonic antigen (CEA) levels (red). These same factors in male patients with squamous cell carcinoma are shown in blue. The Annals of Thoracic Surgery 2016 101, 1877-1882DOI: (10.1016/j.athoracsur.2015.11.067) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions